[新阳药片通过FTO/m6A信号通路改善心力衰竭中的心室重塑]
Dong-Hua Liu1, Zi-Ru Li1, Si-Jing Li1
1State Key Laboratory of Traditional Chinese Medicine Syndrome, the First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou 510407, China the First School of Clinical Medicine, Guangzhou University of Chinese Medicine Guangzhou 510407, China Lingnan Medical Research Center, Guangzhou University of Chinese Medicine Guangzhou 510405, China.
概括
新阳片 (XYP) 通过调节脂肪质量和与肥胖相关的蛋白质 (FTO) /N6-甲基氨酸 (m6A) 途径来改善心力衰竭. XYP治疗减少了心室重塑和心脏纤维化,为心力衰竭提供了潜在的治疗策略.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 涉及心室重塑,这是一个由各种分子途径影响的复杂过程.
- 脂肪质量和与肥胖相关的蛋白质 (FTO) /N6-甲基氨酸 (m6A) 信号通路在与心脏功能相关的细胞过程中发挥作用.
- 研究HF的新型治疗点对于改善患者的治疗结果至关重要.
研究的目的:
- 在心力衰竭模型中阐明新阳片 (XYP) 调节FTO/m6A通路以改善心室重塑的机制.
- 评估XYP对心脏功能,纤维化和重塑分子标记物的影响.
- 在XYP治疗和心肌细胞损伤的背景下探索FTO和m6A修饰的作用.
主要方法:
- 使用横向大动脉收缩 (TAC) 建立了心力衰竭的小鼠模型.
- 给小鼠施用Xinyang片 (XYP) 或二烯多普鲁,并通过心声学评估心脏功能.
- 使用RT-qPCR,马森三色染色,小麦胚芽聚氨酸 (WGA) 染色和免疫组织化学分析心脏组织.
- 在心肌细胞损伤的动物和H9c2细胞模型中研究了FTO/m6A轴和PI3K/Akt信号通路.
主要成果:
- 在HF小鼠模型中,XYP治疗显著改善了心脏功能,并减少了心脏纤维化.
- XYP提高了FTO的表达,并降低了心脏组织中的m6A修饰水平.
- 实验室研究表明,含XYP的血清通过降低m6A水平和PI3K/Akt通路的调节来抑制 ангиотензинII诱导的心肌细胞缩,这种效应被FTO敲击逆转.
结论:
- 新阳片 (XYP) 改善心力衰竭中的心室重塑.
- XYP的治疗效果与FTO/m6A轴的调节有关.
- XYP抑制PI3K/Akt信号通路,这表明治疗心力衰竭的新机制.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
01:22Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291
01:26Heart Failure Drugs: Inotropic Agents
416
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
416
01:22Heart Failure Drugs: β-Blockers
273
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
273